

Rainer Henning, CEO, Biomay AG

Rainer Henning (CEO) has a scientific education as organic chemist. He looks back on a 20 year career in operational and executive positions in the pharmaceutical industry. He held positions as Deputy Head of Cardiovascular Research of Hoechst AG and Managing Director of R&D for the Japanese subsidiary of a Hoechst Marion Roussel, both now being part of Sanofi. He is a co-inventor of two major marketed antihypertensives (ramipril and trandolapril) and author of >65 granted U.S. patents. He was also investment manager and partner at two European venture capital funds (Future Capital and Brilleon Capital). Most recently, he was President & CEO of FIBREX Medical, Inc., a biopharmaceutical company with a focus on acute care medicines. Concurrently, he is CEO of Aposcience AG, a sister company active in the field of regenerative medicine.